The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
Open accessAbstract
Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors (TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR‑mutated non‑small cell lung cancer (NSCLC), and substantially improves their prognosis. However, EGFR T790M mutation is the primary mechanism of 1st‑ and 2nd‑generation EGFR‑TKI resistance. Osimertinib is a representative of the 3rd‑generation EGFR‑TKIs that target T790M mutation, and has satisfactory efficacy in the treatment of T790M‑positive NSCLC with disease progression following use of 1st‑ or 2nd‑generation EGFR‑TKIs. Other 3rd‑generation EGFR‑TKIs, such as abivertinib, rociletinib, nazartinib, olmutinib and alflutinib, are also at various stages of development. However, the occurrence of acquired resistance is inevitable, and the mechanisms of 3rd‑generation EGFR‑TKI resistance are complex and incompletely understood. Genomic studies in tissue and liquid biopsies of resistant patients reveal multiple candidate pathways. The present review summarizes the recent findings in mechanisms of resistance to 3rd‑generation EGFR‑TKIs in advanced NSCLC, and provides possible strategies to overcome this resistance. The mechanisms of acquired resistance mainly include an altered EGFR signaling pathway (EGFR tertiary mutations and amplification), activation of aberrant bypassing pathways (hepatocyte growth factor receptor amplification, human epidermal growth factor receptor 2 amplification and aberrant insulin‑like growth factor 1 receptor activation), downstream pathway activation (RAS/RAF/MEK/ERK and PI3K/AKT/mTOR) and histological/phenotypic transformations (SCLC transformation and epithelial‑mesenchymal transition). The combination of targeted therapies is a promising strategy to treat osimertinib‑resistant patients, and multiple clinical studies on novel combined therapies are ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · cited 4×
“Osimertinib has dominated the global landscape of treatment of EGFR‐positive NSCLC, since it is the current standard of care for the 1st‐line treatment of advanced EGFR‐mutated NSCLC and for EGFR T790M‐positive NSCLC after 1st‐ or 2nd‐generation EGFR‐TKIs (17,19).”
BackgroundInfluentialRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Wu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30608-3 · Cited by 1,216
Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183 · cited 2×
“HER4, uncommon amp, MET amp in 2013 rash (11)”
BackgroundMiller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70087-6 · Cited by 961
EGFR Mutations and Lung Cancer
da Cunha Santos, G., Shepherd, F. A., & Tsao, M. S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130206 · Cited by 949
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C.-H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 886
Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., Bohnet, S., Zhou, C., Lee, K. H., Nogami, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3118 · Cited by 811
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., & Paz-Ares, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx703 · Cited by 766
Oxnard, G. R., Hu, Y., Mileham, K. F., Husain, H., Costa, D. B., Tracy, P., Feeney, N., Sholl, L. M., Dahlberg, S. E., Redig, A. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2969 · Cited by 686 · cited 7×
“KRAS Q61K mutation, BRAF mutations and ESYT2‐BRAF gene fusion have also been detected in patients with acquired osimertinib resistance (57).”
BackgroundMethodInfluentialRociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., Papadimitrakopoulou, V., Solomon, B. J., Oxnard, G. R., Dziadziuszko, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413654 · Cited by 665
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11815 · Cited by 648
Saito, H., Fukuhara, T., Furuya, N., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., Yoshimori, K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30035-x · Cited by 615
Mechanisms of resistance to EGFR tyrosine kinase inhibitors
Huang, L., & Fu, L. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.001 · Cited by 585
Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583
Kim, D.-W., Tiseo, M., Ahn, M.-J., Reckamp, K. L., Hansen, K. H., Kim, S.-W., Huber, R. M., West, H. L., Groen, H. J. M., Hochmair, M. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.5904 · Cited by 581
Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.035 · Cited by 580
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Ramalingam, S. S., Yang, J. C.-H., Lee, C. K., Kurata, T., Kim, D.-W., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7576 · Cited by 547
Yang, Z., Yang, N., Ou, Q., Xiang, Y., Jiang, T., Wu, X., Bao, H., Tong, X., Wang, X., Shao, Y. W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2310 · Cited by 542
Marcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01585 · Cited by 500
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.014 · Cited by 487
Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473
Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468
Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., Fulton, L., Hata, A. N., Lockerman, E. L., Kalsy, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0399 · Cited by 458
Piotrowska, Z., Isozaki, H., Lennerz, J. K., Gainor, J. F., Lennes, I. T., Zhu, V. W., Marcoux, N., Banwait, M. K., Digumarthy, S. R., Su, W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1022 · Cited by 442
Oxnard, G. R., Yang, J. C.-H., Yu, H., Kim, S.-W., Saka, H., Horn, L., Goto, K., Ohe, Y., Mann, H., Thress, K. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.013 · Cited by 438
Sequist, L. V., Han, J.-Y., Ahn, M.-J., Cho, B. C., Yu, H., Kim, S.-W., Yang, J. C.-H., Lee, J. S., Su, W.-C., Kowalski, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30785-5 · Cited by 421
Schoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. C., Paik, P. K., Offin, M., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3563 · Cited by 411
Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., & Katayama, R. (2017) · Nature Communications · doi:10.1038/ncomms14768 · Cited by 409
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
Testa, U., Castelli, G., & Pelosi, E. (2018) · Cancers · doi:10.3390/cancers10080248 · Cited by 403
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Drilon, A., Cappuzzo, F., Ou, S.-H. I., & Camidge, D. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.014 · Cited by 389
Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1542 · Cited by 387
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Ercan, D., Choi, H. G., Yun, C.-H., Capelletti, M., Xie, T., Eck, M. J., Gray, N. S., & Jänne, P. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2789 · Cited by 368
Ramalingam, S. S., Cheng, Y., Zhou, C., Ohe, Y., Imamura, F., Cho, B. C., Lin, M.-C., Majem, M., Shah, R., Rukazenkov, Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.063 · Cited by 366
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Taniguchi, H., Yamada, T., Wang, R., Tanimura, K., Adachi, Y., Nishiyama, A., Tanimoto, A., Takeuchi, S., Araujo, L. H., Boroni, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08074-0 · Cited by 356
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
To, C., Jang, J., Chen, T., Park, E., Mushajiang, M., De Clercq, D. J. H., Xu, M., Wang, S., Cameron, M. D., Heppner, D. E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0903 · Cited by 330
Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0116 · Cited by 297
Wu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D. S. W., Yang, J. C.-H., Azrif, M., Mitsudomi, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 291
Shi, Y. K., Wang, L., Han, B. H., Li, W., Yu, P., Liu, Y. P., Ding, C. M., Song, X., Ma, Z. Y., Ren, X. L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx359 · Cited by 287
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
Yang, J. C.-H., Schuler, M., Popat, S., Miura, S., Heeke, S., Park, K., Märten, A., & Kim, E. S. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.126 · Cited by 274
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Wang, Q., Yang, S., Wang, K., & Sun, S.-Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0759-9 · Cited by 263
Papadimitrakopoulou, V. A., Wu, Y.-L., Han, J.-Y., Ahn, M.-J., Ramalingam, S. S., John, T., Okamoto, I., Yang, J. C.-H., Bulusu, K. C., Laus, G., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.064 · Cited by 252
Kazandjian, D., Blumenthal, G. M., Yuan, W., He, K., Keegan, P., & Pazdur, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2266 · Cited by 236
Ahn, M.-J., Yang, J., Yu, H., Saka, H., Ramalingam, S., Goto, K., Kim, S.-W., Yang, L., Walding, A., & Oxnard, G. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30246-5 · Cited by 234
Weng, C.-H., Chen, L.-Y., Lin, Y.-C., Shih, J.-Y., Lin, Y.-C., Tseng, R.-Y., Chiu, A.-C., Yeh, Y.-H., Liu, C., Lin, Y.-T., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0454-2 · Cited by 233
Mechanisms of Acquired Resistance to AZD9291
Kim, T. M., Song, A., Kim, D.-W., Kim, S., Ahn, Y.-O., Keam, B., Jeon, Y. K., Lee, S.-H., Chung, D. H., & Heo, D. S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000688 · Cited by 222
Wang, Z., Yang, J.-J., Huang, J., Ye, J.-Y., Zhang, X.-C., Tu, H.-Y., Han-Zhang, H., & Wu, Y.-L. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.06.017 · Cited by 221
Nagasaka, M., Zhu, V. W., Lim, S. M., Greco, M., Wu, F., & Ou, S.-H. I. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.028 · Cited by 219
Odogwu, L., Mathieu, L., Blumenthal, G., Larkins, E., Goldberg, K. B., Griffin, N., Bijwaard, K., Lee, E. Y., Philip, R., Jiang, X., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0642 · Cited by 218
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0887-2 · Cited by 216
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non–Small Cell Lung Cancer
Arulananda, S., Do, H., Musafer, A., Mitchell, P., Dobrovic, A., & John, T. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.006 · Cited by 182
Yochum, Z. A., Cades, J., Wang, H., Chatterjee, S., Simons, B. W., O’Brien, J. P., Khetarpal, S. K., Lemtiri-Chlieh, G., Myers, K. V., Huang, E. H.-B., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0482-y · Cited by 178
Nukaga, S., Yasuda, H., Tsuchihara, K., Hamamoto, J., Masuzawa, K., Kawada, I., Naoki, K., Matsumoto, S., Mimaki, S., Ikemura, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2359 · Cited by 175
Olmutinib: First Global Approval
Kim, E. S. (2016) · Drugs · doi:10.1007/s40265-016-0606-z · Cited by 170 · cited 1×
“Olmutinib (HM61713), approved by the FDA in December 2015 for the treatment of NSCLC, has potent inhibitory activity against L858R/T790M mutant NSCLC cells (44).”
BackgroundL718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC
Bersanelli, M., Minari, R., Bordi, P., Gnetti, L., Bozzetti, C., Squadrilli, A., Lagrasta, C. A. M., Bottarelli, L., Osipova, G., Capelletto, E., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.019 · Cited by 167
Yang, J. C.-H., Camidge, D. R., Yang, C.-T., Zhou, J., Guo, R., Chiu, C.-H., Chang, G.-C., Shiah, H.-S., Chen, Y., Wang, C.-C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.001 · Cited by 165
Ahn, M., Han, J., Lee, K. H., Kim, S.-W., Kim, D., Lee, Y., Cho, E. K., Kim, J.-H., Lee, G., Lee, J.-S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30504-2 · Cited by 158
Jang, J., To, C., Clercq, D. J. H. D., Park, E., Ponthier, C. M., Shin, B. H., Mushajiang, M., Nowak, R. P., Fischer, E. S., Eck, M. J., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202003500 · Cited by 156
Schrock, A. B., Zhu, V. W., Hsieh, W.-S., Madison, R. W., Creelan, B., Silberberg, J., Costin, D., Bharne, A., Bonta, I. R., Bosemani, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.027 · Cited by 150
Fassunke, J., Müller, F., Keul, M., Michels, S. Y. F., Dammert, M. A., Schmitt, A., Plenker, D., Lategahn, J., Heydt, C., Brägelmann, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07078-0 · Cited by 150
Shi, P., Oh, Y.-T., Deng, L. H., Zhang, G., Qian, G., Zhang, S., Ren, H. J., Wu, G., Legendre, B., Anderson, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1574 · Cited by 148
Yun, J., Hong, M. H., Kim, S., Park, C.-W., Kim, S., Yun, M. R., Kang, H. N., Pyo, K., Lee, S. S., Koh, J. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2906 · Cited by 146
Lin, C.-C., Shih, J.-Y., Yu, C.-J., Ho, C.-C., Liao, W.-Y., Lee, J.-H., Tsai, T.-H., Su, K.-Y., Hsieh, M.-S., Chang, Y.-L., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30480-0 · Cited by 145
Ellis, P. M., Shepherd, F. A., Millward, M. J., Perrone, F., Seymour, L., Liu, G., Sun, S. B., Cho, B. C., Morabito, A., Leighl, N. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70472-3 · Cited by 139
Yu, H. A., Schoenfeld, A. J., Makhnin, A., Kim, R. Y., Rizvi, H. A., Tsui, D. W. Y., Falcon, C. J., Houck-Loomis, B. R., Meng, F., Yang, J. L., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.1260 · Cited by 137
Okura, N., Nishioka, N., Yamada, T., Taniguchi, H., Tanimura, K., Katayama, Y., Yoshimura, A., Watanabe, S., Kikuchi, T., Shiotsu, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2321 · Cited by 127
Jia, Y., Juarez, J., Li, J., Manuia, M., Niederst, M. J., Tompkins, C., Timple, N., Vaillancourt, M.-T., Pferdekamper, A. C., Lockerman, E. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2581 · Cited by 121
Song, H., Jung, K. S., Yoo, K. H., Cho, J., Lee, J. Y., Lim, S. H., Kim, H. S., Sun, J., Lee, S., Ahn, J. S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.093 · Cited by 118
Shi, Y., Zhang, S., Hu, X., Feng, J., Ma, Z., Zhou, J., Yang, N., Wu, L., Liao, W., Zhong, D., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.010 · Cited by 118
FGFR Signaling as a Target for Lung Cancer Therapy
Desai, A., & Adjei, A. A. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.08.003 · Cited by 112
Wang, Y., Yang, N., Zhang, Y., Li, L., Han, R., Zhu, M., Feng, M., Chen, H., Lizaso, A., Tian, Q., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.04.014 · Cited by 106
Rangachari, D., To, C., Shpilsky, J. E., VanderLaan, P. A., Kobayashi, S. S., Mushajiang, M., Lau, C. J., Paweletz, C. P., Oxnard, G. R., Janne, P. A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.07.016 · Cited by 104
Kim, D., Bach, D., Fan, Y., Luu, T.-T.-T., Hong, J., Park, H. J., & Lee, S. K. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1601-6 · Cited by 103
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
van Veggel, B. A. M. H., Vilachã, J. F., Hashemi, S. M. S., Paats, M. S., Monkhorst, K., Heideman, D. A. M., Groves, M. R., Radonic, T., Smit, E. F., Schuuring, E. M. D., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.013 · Cited by 102
Tanimoto, A., Takeuchi, S., Arai, S., Fukuda, K., Yamada, T., Roca, X., Ong, S. T., & Yano, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2271 · Cited by 101
Zhao, M., Zhang, Y., Cai, W., Li, J., Zhou, F., Cheng, N., Ren, R., Zhao, C., Li, X., Ren, S., et al. (2014) · Cancer · doi:10.1002/cncr.28725 · Cited by 92
Namba, K., Shien, K., Takahashi, Y., Torigoe, H., Sato, H., Yoshioka, T., Takeda, T., Kurihara, E., Ogoshi, Y., Yamamoto, H., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0628 · Cited by 92
Hsu, C., Liao, B.-C., Liao, W., Markovets, A. A., Stetson, D., Thress, K. S., & Yang, J. C. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.006 · Cited by 92
Xu, X., Mao, L., Xu, W., Tang, W., Zhang, X., Xi, B., Xu, R., Fang, X., Liu, J., Fang, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0281 · Cited by 87
Knebel, F. H., Bettoni, F., Shimada, A. K., Cruz, M., Alessi, J. V., Negrao, M. V., Reis, L. F. L., Katz, A., & Camargo, A. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.004 · Cited by 82
Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
Oztan, A., Fischer, S., Schrock, A. B., Erlich, R. L., Lovly, C. M., Stephens, P. J., Ross, J. S., Miller, V., Ali, S. M., Ou, S.-H. I., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.002 · Cited by 80
Tan, D. S. W., Leighl, N. B., Riely, G. J., Yang, J. C., Sequist, L. V. D., Wolf, J., Seto, T., Felip, E., Ponce-Aix, S., Jonnaert, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30267-x · Cited by 79
Update to Rociletinib Data with the RECIST Confirmed Response Rate
Sequist, L. V. D., Soria, J., & Camidge, D. R. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1602688 · Cited by 77
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
Passaro, A., Guerini‐Rocco, E., Pochesci, A., Vacirca, D., Spitaleri, G., Catania, C., Rappa, A., Barberis, M. C. P., & de Marinis, F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.003 · Cited by 77
Romaniello, D., Mazzeo, L., Mancini, M., Marrocco, I., Noronha, A., Kreitman, M., Srivastava, S., Ghosh, S., Lindzen, M., Salame, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0450 · Cited by 73
Isobe, K., Hata, Y., Tochigi, N., Kaburaki, K., Kobayashi, H., Makino, T., Otsuka, H., Sato, F., Ishida, F., Kikuchi, N., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000125 · Cited by 71
Qin, Y., Jian, H., Tong, X., Wu, X., Wang, F., Shao, Y. W., & Zhao, X. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12710 · Cited by 71
Goldberg, S. B., Redman, M. W., Lilenbaum, R., Politi, K. A., Stinchcombe, T. E., Horn, L., Chen, E. H., Mashru, S. H., Gettinger, S. N., Melnick, M. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01149 · Cited by 70
Helman, E., Nguyen, M., Karlovich, C., Despain, D., Choquette, A. K., Spira, A. I., Yu, H. A., Camidge, D. R., Harding, T. C., Lanman, R. B., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.07.008 · Cited by 68
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC
van Veggel, B. A. M. H., de Langen, A. J., Hashemi, S. M. S., Monkhorst, K., Heideman, D. A. M., Thunnissen, E., & Smit, E. F. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.012 · Cited by 67
Ou, S. I., Horn, L., Cruz, M. R., Vafai, D., Lovly, C. M., Spradlin, A., Williamson, M. J., Dagogo‐Jack, I., Johnson, A., Miller, V. A., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.07.006 · Cited by 65
Manabe, T., Yasuda, H., Terai, H., Kagiwada, H., Hamamoto, J., Ebisudani, T., Kobayashi, K., Masuzawa, K., Ikemura, S., Kawada, I., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0956 · Cited by 64
Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
Sequist, L. V. D., Piotrowska, Z., Niederst, M. J., Heist, R. S., Digumarthy, S. R., Shaw, A. T., & Engelman, J. A. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5009 · Cited by 62
Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1506831 · Cited by 61
Nakatani, K., Yamaoka, T., Ohba, M., Fujita, K., Arata, S., Kusumoto, S., Taki-Takemoto, I., Kamei, D., Iwai, S., Tsurutani, J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0591 · Cited by 59
Ma, Y., Zheng, X. X., Zhao, H., Fang, W., Zhang, Y., Ge, J., Wang, L., Wang, W., Jiang, J., Chuai, S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.025 · Cited by 58
Hayakawa, D., Takahashi, F., Mitsuishi, Y., Tajima, K., Hidayat, M., Winardi, W., Ihara, H., Kanamori, K., Matsumoto, N., Asao, T., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13255 · Cited by 57
Park, K., Lee, J.-S., Lee, K. H., Kim, J.-H., Min, Y. J., Choi, Y., Han, J., Kim, B.-S., Kim, J.-S., Lee, K. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8084 · Cited by 54
Hasegawa, H., Yasuda, H., Hamamoto, J., Masuzawa, K., Tani, T., Nukaga, S., Hirano, T., Kobayashi, K., Manabe, T., Terai, H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.039 · Cited by 54
Zhao, J., Zou, M., Lv, J., Han, Y., Wang, G., & Wang, G. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170358 · Cited by 49
Zhang, Y., Chen, Z., Zhang, X., Xu, C., Yan, H., Xie, Z., Chuai, S., Ye, J., Han‐Zhang, H., Zhang, Z., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.04.030 · Cited by 47
Gu, J., Yao, W., Shi, P., Zhang, G., Owonikoko, T. K., Ramalingam, S. S., & Sun, S. (2020) · Cancer · doi:10.1002/cncr.32996 · Cited by 44
Zhao, S., Li, X., Zhao, C., Jiang, T., Jia, Y., Shi, J., He, Y., Li, J., Zhou, F., Gao, G., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.010 · Cited by 41
Rotow, J. K., Costa, D. B., Paweletz, C. P., Awad, M. M., Marcoux, P. J., Rangachari, D., Barbie, D. A., Sands, J. M., Cheng, M. L., Johnson, B. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9507 · Cited by 40
Cho, B. C., Lee, K. H., Cho, E. K., Kim, D.-W., Lee, J. S., Han, J.-Y., Kim, S.-W., Spira, A. I., Haura, E. B., Sabari, J. K., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1572 · Cited by 39
Han, R., Hao, S., Lu, C., Zhang, C., Lin, C., Li, L., Wang, Y., Hu, C., & He, Y. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12682 · Cited by 36
Kelly, R. J., Shepherd, F. A., Krivoshik, A., Jie, F., & Horn, L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz128 · Cited by 35
Chic, N., Mayo‐de‐las‐Casas, C., & Reguart, N. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.02.014 · Cited by 34
Kim, D., Lee, K. H., Han, J., Lee, J.-S., Cho, B. C., Kang, J. H., Lee, K. H., Cho, E. K., Kim, J.-S., Min, Y. J., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.07.007 · Cited by 34
Park, S., Ku, B. M., Jung, H. A., Sun, J., Ahn, J. S., Lee, S., Park, K., & Ahn, M. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.278 · Cited by 32
Safety of osimertinib in EGFR -mutated non-small cell lung cancer
Mezquita, L., Varga, A., & Planchard, D. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1549222 · Cited by 31
Yu, H. A., Spira, A. I., Horn, L., Weiss, J. M., West, H., Giaccone, G., Evans, T. L., Kelly, R. J., Desai, B., Krivoshik, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1447 · Cited by 29
Li, X., Wang, S., Li, B., Wang, Z., Shang, S., Shao, Y. W., Sun, X., & Wang, L. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0573-2 · Cited by 29
Oh, D. K., Ji, W., Kim, W. S., Choi, C., Yoon, S., Rho, J. K., & Lee, J. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210225 · Cited by 29
Zhang, Y., Zhou, Q. H., & Wu, Y.-L. L. C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.044 · Cited by 27
Batra, U., Sharma, M., Amrith, B. P., Mehta, A., & Jain, P. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.05.016 · Cited by 27
Xie, Z., Gu, Y., Xie, X., Lin, X., Ouyang, M., Qin, Y., Zhang, J., Lizaso, A., Chen, S., & Zhou, C. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.06.008 · Cited by 27
Leprieur, E. G., Duménil, C., & Chinet, T. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.012 · Cited by 25
Yang, X., Huang, C., Chen, R., & Zhao, J. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.12.002 · Cited by 25
Wang, H., Zhang, L., Hu, P., Zheng, X., Si, X., Zhang, X., & Wang, M. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.010 · Cited by 21
Yang, Y., Jang, Y. J., Lee, S., Kang, B., & Lim, S. M. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.031 · Cited by 20
Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Horn, L., Costa, D. B., Tsao, A. S., Patel, J., Gadgeel, S. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1575 · Cited by 18
Wang, H., Pan, R., Zhang, X., Si, X., Wang, M., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13302 · Cited by 16
Fang, W., Huang, Y., Gan, J., Shao, Y. W., & Zhang, L. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.023 · Cited by 13
Liu, S. M., Zhou, J., Li, W., Sun, H., Zhang, Y., Yan, H., Chen, Z., Chen, C., Ye, J., Yang, J., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.12 · Cited by 12
Zhou, J., Zhou, F., Xie, H., Wu, Y., Zhao, J., & Su, C. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.02.09 · Cited by 9
Kobayashi, N., Hashimoto, H., Kamimaki, C., Nagasawa, R., Tanaka, K., Kubo, S., Katakura, S., Chen, H., Hirama, N., Ushio, R., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13503 · Cited by 4
Cited by
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
Metadata
- Authors
- He, J., Huang, Z., Han, L., Gong, Y., & Xie, C.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2021-09-24
- Volume
- 59
- Issue
- 5
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W3200033087
- Cited by
- 314
- References
- 134
- FWCI
- 25.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.